SVCM
Saturn V Capital Management Portfolio holdings
AUM
$247M
This Quarter Return
-13.14%
1 Year Return
+2.68%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$198M
AUM Growth
+$198M
(-22%)
Cap. Flow
-$18.5M
Cap. Flow
% of AUM
-9.32%
Top 10 Holdings %
Top 10 Hldgs %
77.38%
Holding
25
New
1
Increased
11
Reduced
9
Closed
4
Top Buys
| 1 |
CNTA
Centessa Pharmaceuticals
CNTA
|
$6.45M |
| 2 |
Amylyx Pharmaceuticals
AMLX
|
$5.44M |
| 3 |
Merus
MRUS
|
$3.73M |
| 4 |
Xenon Pharmaceuticals
XENE
|
$3.06M |
| 5 |
Ocular Therapeutix
OCUL
|
$2.98M |
Top Sells
| 1 |
Cytokinetics
CYTK
|
$16.4M |
| 2 |
CRGX
CARGO Therapeutics
CRGX
|
$14.5M |
| 3 |
Ironwood Pharmaceuticals
IRWD
|
$3.61M |
| 4 |
argenx
ARGX
|
$3.49M |
| 5 |
KalVista Pharmaceuticals
KALV
|
$3.48M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Ascendis Pharma
ASND
$11.8B
| $31.1M | 15.67% |
199,264
+287
| +0.1% | +$44.7K |
|
2
Disc Medicine
IRON
$2.07B
| $25.7M | 12.98% |
518,177
+8,771
| +2% | +$435K |
|
3
CG Oncology
CGON
$2.04B
| $14.1M | 7.14% |
577,696
-15,566
| -3% | -$381K |
|
|
4
Xenon Pharmaceuticals
XENE
$2.98B
| $13.9M | 7% |
413,711
+91,241
| +28% | +$3.06M |
|
|
5
Merus
MRUS
$4.98B
| $13.6M | 6.87% |
323,211
+88,574
| +38% | +$3.73M |
|
6
MoonLake Immunotherapeutics
MLTX
$3.54B
| $13.4M | 6.78% |
343,849
-2,262
| -0.7% | -$88.4K |
|
7
Syndax Pharmaceuticals
SNDX
$1.41B
| $12.8M | 6.46% |
1,041,280
+52,752
| +5% | +$648K |
|
8
Celcuity
CELC
$2.17B
| $11.1M | 5.58% |
1,093,677
+29,894
| +3% | +$302K |
|
9
Cogent Biosciences
COGT
$1.69B
| $8.87M | 4.47% |
1,480,020
-18,405
| -1% | -$110K |
|
10
Vaxcyte
PCVX
$4B
| $8.77M | 4.43% |
232,295
+28,010
| +14% | +$1.06M |
|
|
11
Amylyx Pharmaceuticals
AMLX
$836M
| $8.59M | 4.33% |
2,426,436
+1,537,363
| +173% | +$5.44M |
|
|
12
argenx
ARGX
$43.6B
| $8.2M | 4.14% |
13,862
-5,892
| -30% | -$3.49M |
|
|
CNTA
13
Centessa Pharmaceuticals
CNTA
$2.25B
| $6.45M | 3.26% |
+448,692
| New | +$6.45M |
|
|
14
Ocular Therapeutix
OCUL
$2.12B
| $4.38M | 2.21% |
598,191
+406,735
| +212% | +$2.98M |
|
|
CTNM
15
Contineum Therapeutics
CTNM
$293M
| $3.92M | 1.98% |
560,979
-12,043
| -2% | -$84.1K |
|
|
ABVX
16
Abivax
ABVX
$6.12B
| $3.46M | 1.74% |
552,926
-100,145
| -15% | -$626K |
|
|
17
KalVista Pharmaceuticals
KALV
$678M
| $2.94M | 1.49% |
255,060
-301,429
| -54% | -$3.48M |
|
18
NewAmsterdam Pharma
NAMS
$2.71B
| $2.38M | 1.2% |
116,353
+16,353
| +16% | +$335K |
|
|
SLN
19
Silence Therapeutics
SLN
$227M
| $2.07M | 1.04% |
732,463
+337,439
| +85% | +$952K |
|
20
Crinetics Pharmaceuticals
CRNX
$2.92B
| $1.98M | 1% |
59,017
-108
| -0.2% | -$3.62K |
|
|
INZY
21
DELISTED
Inozyme Pharma
INZY
| $454K | 0.23% |
499,254
-875,328
| -64% | -$797K |
|
|
22
Cytokinetics
CYTK
$4.23B
| – | – |
-348,364
| Closed | -$16.4M |
|
|
23
Ironwood Pharmaceuticals
IRWD
$214M
| – | – |
-814,533
| Closed | -$3.61M |
|
|
MBX
24
MBX Biosciences, Inc. Common Stock
MBX
$507M
| – | – |
-18,000
| Closed | -$332K |
|
|
CRGX
25
DELISTED
CARGO Therapeutics
CRGX
| – | – |
-1,007,677
| Closed | -$14.5M |
|